Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07533045 · ClinicalTrials.gov registry record · NA

Effects of Paraxanthine Supplementation on eSport Performancre

A NA study, sponsored by Lindenwood University.

Completed
Registry status
NA
Development phase
60
Enrollment target

NCT07533045: Completed NA study, sponsored by Lindenwood University.

NCT07533045 is a NA study that has completed, run by Lindenwood University. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07533045, a NA study, has completed, sponsored by Lindenwood University.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target

Study Summary

This study will evaluate the effects of daily paraxanthine supplementation on electronic gaming performance, cognitive function, sleep quality, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and assigned to receive either paraxanthine or placebo daily for 6 weeks. Outcome measures will be assessed at baseline, Week 3, and Week 6 and will include electronic gaming performance, cognitive function, visual analog scale ratings, sleep quality questionnaires, hemodynamic responses, and heart rate variability. The study is designed to determine whether paraxanthine supplementation improves performance and selected physiological and psychological outcomes during prolonged electronic gaming sessions.

Primary Outcome

Electronic gaming performance will be assessed using standardized gameplay metrics collected during 60- and 120-minute gaming sessions. Primary variables include knock-outs, falls, damage given, damage taken, hit percentage, and peak damage.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Paraxanthine

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2021-06-15
Est. Completion 2025-04-14
Phase NA
Lindenwood University

29 total trials

What the finished NCT07533045 record still lists

NCT07533045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07533045 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07533045 about?

NCT07533045 is a clinical study titled "Effects of Paraxanthine Supplementation on eSport Performancre". This study will evaluate the effects of daily paraxanthine supplementation on electronic gaming performance, cognitive function, sleep quality, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and a...

What is the current status of trial NCT07533045?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2021-06-15. Estimated completion is 2025-04-14.

What interventions are being tested in trial NCT07533045?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Paraxanthine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07533045?

This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07533045's enrollment target sits among peer trials

60 1164th of 2000 higher than 745 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07533045, the US trial registry maintained by the National Library of Medicine. NCT07533045 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.